Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company that regularly issues news on its business segments, financing activities, partnerships and product pipeline. As an ophthalmic goods manufacturer with operations in vision care, surgical products and ophthalmic pharmaceuticals, the company’s announcements cover a broad range of topics relevant to investors and those following the eye health sector.
News updates include financial results, such as quarterly revenue performance across the Vision Care, Surgical and Pharmaceuticals segments, as well as details on operating income, adjusted metrics and guidance ranges. The company also uses press releases to outline strategic plans and multi-year financial targets, describe its product pipeline in areas like dry eye, glaucoma, ocular surface pain and age-related macular degeneration, and highlight clinical-stage programs and anticipated launches across consumer, pharmaceutical, surgical and contact lens businesses.
Bausch + Lomb’s news flow also features information on capital structure and liquidity, including amendments to its credit agreement, new term loan tranches, revolving credit facilities and senior secured notes offerings, along with the intended use of proceeds for refinancing existing debt. Governance and leadership developments, such as board appointments, committee assignments and changes related to director nomination agreements, are disclosed through current reports and accompanying press releases.
In addition, the company issues news about partnerships and initiatives in eye health, including collaborations with organizations focused on glaucoma research and awareness, and sustainability programs like the ONE by ONE Recycling Program and the Every Contact Counts program. For readers tracking BLCO, this news page aggregates these updates so they can review company communications on financial performance, strategic direction, product development, governance and eye health initiatives in one place.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health leader, will present a company update at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:00 p.m. PT. This presentation will highlight recent performance, achievements, and future goals for the company. The presentation can be accessed on their Investor Relations page. With over 400 products, Bausch + Lomb is committed to enhancing vision for individuals worldwide, supported by a robust global presence.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:00 p.m. PT. CEO Joseph C. Papa and CFO Sam Eldessouky will represent the company, which focuses on eye health products. A live webcast will be available on the company’s Investor Relations page. Founded in 1853, Bausch + Lomb offers over 400 products, including contact lenses and ophthalmic surgical devices, serving customers in nearly 100 countries.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) and Novaliq GmbH are advancing NOV03, a new ophthalmic solution targeting dry eye disease linked to Meibomian gland dysfunction. Recent publication in Ophthalmology highlights positive results from the pivotal Phase 3 GOBI trial, meeting all co-primary endpoints with statistical significance achieved as early as day 15. The FDA has set a PDUFA date of June 28, 2023 for NOV03's review, which could provide a much-needed treatment option for millions suffering from this condition.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched the ‘Screen, Protect, Cure’ campaign to raise awareness about glaucoma during Glaucoma Awareness Month. This initiative aims to educate at-risk individuals on the importance of early detection and treatment. The campaign features a fundraising challenge matching up to $20,000 for glaucoma research. Currently, about three million people in the U.S. are affected by this sight-threatening disease, highlighting the need for continued education and research in eye health.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced that CEO Joseph C. Papa will continue in his role until at least March 4, 2023, per an Amended Separation Agreement. The agreement allows for potential extensions until June 30, 2023, depending on the Board's discretion or the appointment of a successor. Changes to Papa's compensation were also noted. Bausch + Lomb is a global eye health leader with a portfolio exceeding 400 products, and it operates in nearly 100 countries. For more information, visit www.bausch.com.
Bausch + Lomb (NYSE: BLCO) has received FDA 510(k) clearance for its Biotrue Hydration Boost Contact Lens Rehydrating drops. This preservative-free product is designed for soft and rigid gas permeable lenses, providing up to eight hours of moisture. With one-third of the 45 million U.S. contact lens wearers experiencing dryness, this product is expected to cater to a significant market need. The drops contain hyaluronan and match the pH of healthy tears, enhancing user comfort. Availability is anticipated in the first half of 2023.
Bausch + Lomb (NYSE/TSX: BLCO) announced its ONE by ONE and Biotrue Eye Care Recycling programs have won the gold award for 'Most Environmentally Friendly Service of the Year' at the 2022 Best in Biz Awards. Joe Gordon, president of Global Consumer, emphasized the company's commitment to sustainability, highlighting progress in recycling over 60 million used contact lenses and eye care materials. These programs aim to address plastic pollution by enabling the proper recycling of items typically not accepted in standard facilities.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced that its new contact lens solution, Biotrue Hydration Plus, has won the 2022 BIG Awards for Business Product of the Year from Business Intelligence Group. This innovative solution enhances moisture retention for contact lens wearers, providing all-day comfort and exceptional disinfection with a triple disinfectant system. It incorporates bio-inspired ingredients, including 25% more hyaluronan, potassium, and erythritol, to match the pH of healthy tears, addressing the needs of patients suffering from contact lens dryness.
Bausch + Lomb (NYSE/TSX: BLCO) has announced that its innovative recycling programs, ONE by ONE and Biotrue Eye Care, have successfully collected over 58 million units (approximately 356,723 pounds) of used contact lenses and related materials since their inception. This effort, in collaboration with TerraCycle, helps reduce environmental pollution caused by non-biodegradable plastics in the U.S. The ONE by ONE program has been active since November 2016, while the Biotrue program began in April 2021. These initiatives highlight Bausch + Lomb's commitment to sustainability.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) will participate in the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:40 a.m. ET. The event will feature CEO Joseph C. Papa and CFO Sam Eldessouky. A webcast of the presentation will be available on the company's Investor Relations page.
Founded in 1853, Bausch + Lomb is a global leader in eye health, offering over 400 products, including contact lenses and ophthalmic pharmaceuticals. The company is headquartered in Vaughan, Ontario, with a significant global presence.